Xenetic Biosciences (NASDAQ: XBIO) again adjourns 2025 shareholder meeting for lack of quorum

Rhea-AI Filing Summary

Xenetic Biosciences, Inc. reported that its 2025 Annual Meeting of Stockholders, originally adjourned from December 11, 2025 to January 8, 2026 to seek more proxies and achieve a quorum, was again adjourned on January 8, 2026 without any business being conducted because a sufficient number of shares was not represented.

The company plans to reconvene the Annual Meeting at a future date and time that has not yet been set and will give stockholders the required advance notice before the new meeting.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Understanding 8-K Material Events →

false 0001534525 0001534525 2026-01-08 2026-01-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________________

FORM 8-K

________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 8, 2026

________________________

Xenetic Biosciences, Inc.

(Exact name of registrant as specified in charter)

Nevada		001-37937		45-2952962
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

945 Concord Street
Framingham, Massachusetts	01701
(Address of principal executive offices)	(Zip Code)

(781) 778-7720

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value per share		XBIO		The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On December 11, 2025, Xenetic Biosciences, Inc. (the “Company”) announced that its 2025 Annual Meeting of Stockholders (the “Annual Meeting”), originally scheduled for December 11, 2025, had been adjourned until January 8, 2026 in order to achieve a quorum and allow additional time to solicit proxies on behalf of the Company’s board of directors.

On January 8, 2026, the Company reconvened and again adjourned the Annual Meeting, without any business being conducted, due to lack of a requisite quorum. The Company intends to reconvene the Annual Meeting at a new date and time that has yet to be determined, and will provide stockholders with requisite advance notice of such meeting date and time.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	XENETIC BIOSCIENCES, INC.
	By:	/s/ James Parslow
Date: January 9, 2026	Name:	James Parslow
	Title:	Interim Chief Executive Officer and Chief Financial Officer

3

FAQ

What did Xenetic Biosciences (XBIO) disclose in this 8-K filing?

The company disclosed that its 2025 Annual Meeting of Stockholders, adjourned from December 11, 2025 to January 8, 2026, was again adjourned on January 8, 2026 due to not having a quorum, and no business was conducted.

Why was the Xenetic Biosciences (XBIO) 2025 Annual Meeting adjourned again?

The meeting on January 8, 2026 was adjourned because there was a lack of the requisite quorum, meaning not enough shares were represented to legally conduct business.

Has Xenetic Biosciences (XBIO) set a new date for the 2025 Annual Meeting?

No new date is provided in the content. The company states that it intends to reconvene the Annual Meeting at a new date and time that has yet to be determined and will provide stockholders with requisite advance notice.

Was any business conducted at the Xenetic Biosciences (XBIO) Annual Meeting on January 8, 2026?

No. The company states that the Annual Meeting was reconvened and again adjourned on January 8, 2026 without any business being conducted because a quorum was not present.

Who signed the Xenetic Biosciences (XBIO) 8-K related to the adjourned Annual Meeting?

The report was signed on behalf of Xenetic Biosciences, Inc. by James Parslow, who is identified as Interim Chief Executive Officer and Chief Financial Officer.

What was the originally scheduled date for Xenetic Biosciences (XBIO) 2025 Annual Meeting?

The 2025 Annual Meeting of Stockholders was originally scheduled for December 11, 2025 before being adjourned first to January 8, 2026 and then adjourned again on that date.